ArticleJournal of nanobiotechnology2026
Identification of efficient multi-epitope combinations against African swine fever virus based on AP205 scaffold-mediated nanodisplay technology.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and Evaluation of Three Indirect ELISA Methods Based on Novel Recombinant ASFV Antigens for Serological Detection of African Swine Fever.Pathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAfrican swine fever virus (ASFV), characterized by its large genome and high antigenic diversity, has impeded the development of traditional vaccines. In this study, we employed the AP205 capsid protein as the scaffold to prepare ASFV multi-epitope nanoparticles via sequential steps: fusion of the scaffold gene with ASFV multi-epitope genes, followed by recombinant protein expression, purification, in vitro self-assembly, structural characterization, and immune evaluation in BALB/c mice.
resultsIt was found that the dimeric AP205 scaffold enhanced the assembly efficiency of nanoparticles harboring epitopes of ASFV, and the recombinant proteins DB, 22C, and DE, fused with the scaffold and the epitopes, all formed virus-like particles (VLPs). Immunization experiments demonstrated that DE, which carries the linear B-cell epitopes pB438L 51-73, p72 244-262, and p54 132-180, exhibited the optimal immunological efficacy, with outstanding performance in immunoreactivity, immunogenicity, specific antibody titers, immune cell activation, and inhibition of ASFV nucleic acid replication by immune serum. The nanoparticle DF (carrying linear B-cell epitopes p17 5-34, 71-113, and p30 4-15) showed comparable or even superior efficacy in all aspects except for slightly lower antibody levels, while DB (carrying linear B-cell epitopes p17 68-86, pE248R 138-168, 158-185) and 22C (carrying linear B-cell epitopes pE120R 65-117, pE199L 175-189, pO61R 36-56) yielded moderate efficacy.
conclusionsThe dimeric AP205 scaffold tolerates the insertion of exogenous antigen fragments with greater complexity and size, and its simplified fusion display strategy facilitates commercial production. The spatial structure of VLPs confers significant advantages in inducing efficient immune responses. Furthermore, the VLP structures designed and validated in this study provide valuable data for amino acid deconstruction of analogous architectures. Meanwhile, this study identified efficient and precise ASFV epitope combinations, providing informative data to support the application of ASFV multi-epitope nanoparticle vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.